Introduction

For many people living with knee osteoarthritis, finding effective pain relief without resorting to surgery is a top priority. Arthrosamid is an exciting injectable treatment that has been gaining attention as a non-surgical way to ease osteoarthritis symptoms by cushioning and supporting the knee joint. In this article, we explore how long this relief typically lasts, drawing on scientific studies, clinical findings, and patient experiences. Throughout, you’ll see key terms like “Arthrosamid duration” and “knee injection longevity,” helping to clarify just how durable this treatment can be.

Understanding Arthrosamid and How It Works Over Time

Arthrosamid is a hydrogel, made from 2.5% cross-linked polyacrylamide, which is injected straight into the knee joint. Its main job is to act like a soft scaffold inside the synovial membrane—the lining around the joint—helping to reduce pressure and inflammation caused by osteoarthritis. Once in place, the gel integrates with nearby tissues, creating a cushioned environment that helps ease pain and improve movement. As one 2022 review explains, “It adheres to and bulks up the synovial membrane and acts as a scaffold to treat the synovium.” Many patients want to know how long these effects last. The relief from Arthrosamid can span from several months up to a few years, depending on how the hydrogel interacts with the knee tissues over time.

What Clinical Studies and Reviews Tell Us About Duration

The lasting benefits of Arthrosamid have been studied carefully. A systematic review looking at 463 patients reported that “statistically significant data was identified in two studies at both 52 weeks and 13 months, indicating the efficacy of PAAG hydrogel at one year post injection.” Impressively, another study followed patients for two years and found the positive effects still held, stating, “Further continuation of one of these studies provided statistically significant results at 2 years.” In fact, the review mentions that Arthrosamid showed “[n]umerically superior data … compared to hyaluronic acid” injections, which are more commonly used.

Comparing Arthrosamid to other treatments, a recent study showed it “outperformed Steroid at 6 months (P < .001), but not HA (P = 1.000). No significance at 12 months (P = .128).” This study also found that “At 12 months, HA and Steroid returned to baseline, while iPAAG remained slightly improved (P = .219).”

Safety is crucial for any treatment, and laboratory tests add reassurance. Research into the compound found that “2.5 iPAAG had no statistically significant effects on cell survival, non-apoptotic and apoptotic cell death, or the neurite network area,” concluding it “demonstrates no apparent in vitro neurotoxic or cytotoxic effects.”

Overall, research consistently shows that Arthrosamid can provide relief lasting from 12 to 24 months, and sometimes even up to three years. However, as osteoarthritis progresses naturally, some degree of symptom return over time is expected.

What Influences How Long Relief Lasts?

How long you benefit from Arthrosamid can vary depending on several important factors. For example, the stage of osteoarthritis matters—a person with moderate joint damage often enjoys longer-lasting relief than someone with more advanced degeneration. Age and levels of physical activity also play a role, as highly active individuals may experience a shorter duration of benefit due to more joint use. Other health issues like obesity or inflammation can influence outcomes too. Additionally, the skill of the clinician administering the injection and how well patients follow aftercare advice can affect effectiveness. Experts agree that these factors lead to different experiences among patients, which is why personalised treatment plans and regular follow-ups are so important. Usually, when relief begins to fade, patients notice a gradual return of pain and stiffness, which healthcare providers monitor to decide whether further treatment is needed.

What to Expect: The Timeline of Relief and Repeat Injections

After receiving an Arthrosamid injection, patients can expect relief to begin within a few weeks, as the gel settles and starts easing pressure in the joint. The best effects are often seen within the first six months, with significant pain reduction and better movement reported during this time. The systematic review highlights that “this PAAG hydrogel seems to be an efficacious and safe treatment option for knee OA and provides positive results for at least 2 years.”

In comparative studies, Arthrosamid patients showed the highest rates of acceptable symptom relief, with “72%, 54%, and 42% at 3, 6, and 12 months.” Still, the same research points out that “overall differences at 12 months were significant … but pairwise comparisons were not,” meaning the long-term advantage is modest rather than dramatic.

As time goes on, the cushioning effect may lessen, or osteoarthritis may advance, so some return of symptoms can be expected. When this happens, repeat injections might be recommended. Experts encourage patients to keep track of their pain and function and consult healthcare professionals when symptoms start to worsen again. This approach helps ensure the best possible long-term management and confirms Arthrosamid as a durable choice among lasting osteoarthritis treatments.

Conclusion

Arthrosamid knee injections offer a scientifically supported, non-surgical way to manage osteoarthritis pain with relief lasting up to three years and a reassuring safety profile. Results can vary based on the severity of joint damage, the patient’s lifestyle, and how the treatment is delivered, so working closely with a healthcare provider is key. Staying informed by current research helps patients make the best choices for their joint health. Overall, Arthrosamid is a reliable and effective option for those seeking long-lasting relief from knee osteoarthritis.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(14), e44655. https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina-Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430